Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Biomarker Research

Table 1 Predictive factors for PD-1/PD-L1 blockade therapy

Tumor type	Agent	Predictive factor	Reference
Non-small cell lung cancer	Atezolizumab	PD-L1	[68]
Multiple cancers	Pembrolizumab	PD-L1	[69]
Colorectal cancer	Nivolumab	MMR / MSI	[70]
Urothelial carcinoma	Atezolizumab	TMB	[71]
Urothelial carcinoma	Atezolizumab	TMB	[72]
Urothelial cancer	Atezolizumab	TMB	[73]
Melanoma	Anti-PD-1 therapy	Gut microbiome	[74]
Melanoma	Anti-PD-1 therapy	Gut microbiome	[75]
Melanoma	Anti-PD-1 therapy	Gut microbiome	[61]

MMR: mismatch repair; MSI: microsatellite instability; TMB: tumor mutation burden

ISSN: 2050-7771